Clinical DataPhase 1/2 trial data of INO-3107 for the treatment of RRP showed that the treatment induced new populations of T cells, correlated with a reduction in the number of post-treatment surgeries, and was well tolerated.
Manufacturing ResolutionInovio Pharmaceuticals believes the device manufacturing issues for DNA immunotherapy INO-3107 have been resolved, supporting a BLA acceptance.
Market StrategyInovio has developed a distribution/channel strategy, identified channel partners, developed an initial pricing strategy, completed targeting/segmentation and product positioning work, and is developing a go-to-market model.